Bispecific monoclonal antibodies (BiMAb) have been shown to be able to cont
ribute to an immunological approach in cancer therapy. In this review, esse
ntial aspects regarding the production of BiMAb and modes to apply them in
immunotherapy for cancer are discussed. The pros and cons of BiMAb are cons
idered, and the development from application in animal models to clinical s
tudies is reviewed. The most important clinical trials are summarized, and
the different problems encountered are discussed. Provided some crucial pro
blems can be overcome, BiMAb will have a place in the treatment of cancer,
especially in the setting of minimal residual disease.